Connect Biopharma Holdings ( (CNTB) ) has shared an announcement.
On March 28, 2025, Connect Biopharma Holdings announced it received a Nasdaq deficiency notice due to its American Depositary Shares (ADSs) closing below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until September 22, 2025, to regain compliance, and its shares will continue trading on the Nasdaq Global Market. If compliance is not achieved, Connect Biopharma may qualify for an additional 180-day period by transferring to the Nasdaq Capital Market, but risks delisting if the deficiency is not resolved.
More about Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD). Headquartered in San Diego, California, the company is advancing rademikibart, an anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which has shown promising results in reducing exacerbations and improving lung function in asthma patients.
YTD Price Performance: -37.19%
Average Trading Volume: 19,935
Technical Sentiment Signal: Buy
Current Market Cap: $41.99M
Find detailed analytics on CNTB stock on TipRanks’ Stock Analysis page.